Related Experiment Video

Updated: Oct 15, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma

Jessica C Hassel1

  • 1Section of DermatoOncology, Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. jessica.hassel@med.uni-heidelberg.de.

British Journal of Cancer
|October 26, 2021
PubMed

Insights

Immune checkpoint inhibitors improve melanoma survival but can cause side effects. These immune-related adverse events may indicate a better clinical response, according to new research.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity and improve survival in metastatic melanoma.
  • However, ICIs can trigger immune-related adverse events (irAEs), which are autoimmune side effects.
  • The clinical significance of irAEs in predicting treatment response remains an area of active investigation.

Discussion:

  • Ye et al. conducted a retrospective analysis to investigate the relationship between irAEs and clinical benefit from ICIs in metastatic melanoma.
  • The study explored whether irAEs serve as predictive biomarkers for treatment outcomes.
  • Findings suggest a correlation between the occurrence of irAEs and improved patient survival or response.

Key Insights:

  • Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) may serve as predictive biomarkers for clinical benefit in metastatic melanoma.
  • Patients experiencing irAEs demonstrated differential gene expression patterns, particularly in chemokine-mediated signaling pathways.
  • This suggests a biological link between the immune system's response to ICIs and the development of irAEs, potentially influencing treatment efficacy.

Outlook:

  • Further prospective studies are warranted to validate irAEs as reliable biomarkers for ICI therapy in melanoma.
  • Investigating the specific chemokine pathways involved could lead to novel therapeutic strategies.
  • Understanding the immunobiology underlying irAEs may help optimize ICI treatment and patient management.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

807

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
736